Compare with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES DR. REDDYS LAB ALKEM LABORATORIES/
DR. REDDYS LAB
 
P/E (TTM) x - 22.3 - View Chart
P/BV x 6.6 3.3 198.9% View Chart
Dividend Yield % 0.7 0.7 92.2%  

Financials

 ALKEM LABORATORIES   DR. REDDYS LAB
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
DR. REDDYS LAB
Mar-19
ALKEM LABORATORIES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,5892,875 55.3%   
Low Rs1,2321,888 65.3%   
Sales per share (Unadj.) Rs417.5930.2 44.9%  
Earnings per share (Unadj.) Rs56.3117.4 47.9%  
Cash flow per share (Unadj.) Rs64.7185.8 34.8%  
Dividends per share (Unadj.) Rs12.7020.00 63.5%  
Dividend yield (eoy) %0.90.8 107.2%  
Book value per share (Unadj.) Rs292.9844.4 34.7%  
Shares outstanding (eoy) m119.57166.07 72.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.6 132.0%   
Avg P/E ratio x25.120.3 123.5%  
P/CF ratio (eoy) x21.812.8 170.0%  
Price / Book Value ratio x4.82.8 170.7%  
Dividend payout %22.617.0 132.4%   
Avg Mkt Cap Rs m168,653395,496 42.6%   
No. of employees `000NA22.0 0.0%   
Total wages/salary Rs m9,17133,562 27.3%   
Avg. sales/employee Rs ThNM7,032.8-  
Avg. wages/employee Rs ThNM1,527.9-  
Avg. net profit/employee Rs ThNM887.7-  
INCOME DATA
Net Sales Rs m49,915154,482 32.3%  
Other income Rs m1,6453,375 48.7%   
Total revenues Rs m51,561157,857 32.7%   
Gross profit Rs m8,48231,782 26.7%  
Depreciation Rs m1,00611,348 8.9%   
Interest Rs m671889 75.4%   
Profit before tax Rs m8,45122,920 36.9%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6063,858 41.6%   
Profit after tax Rs m6,73119,500 34.5%  
Gross profit margin %17.020.6 82.6%  
Effective tax rate %19.016.8 112.9%   
Net profit margin %13.512.6 106.8%  
BALANCE SHEET DATA
Current assets Rs m27,062111,101 24.4%   
Current liabilities Rs m15,32458,973 26.0%   
Net working cap to sales %23.533.7 69.7%  
Current ratio x1.81.9 93.7%  
Inventory Days Days6779 83.8%  
Debtors Days Days4194 43.8%  
Net fixed assets Rs m12,610101,245 12.5%   
Share capital Rs m239830 28.8%   
"Free" reserves Rs m34,490139,406 24.7%   
Net worth Rs m35,027140,236 25.0%   
Long term debt Rs m1,21222,000 5.5%   
Total assets Rs m54,387224,656 24.2%  
Interest coverage x13.626.8 50.8%   
Debt to equity ratio x00.2 22.0%  
Sales to assets ratio x0.90.7 133.5%   
Return on assets %13.69.1 150.0%  
Return on equity %19.213.9 138.2%  
Return on capital %24.914.9 166.3%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56388,673 7.4%   
Fx outflow Rs m3,01219,104 15.8%   
Net fx Rs m3,55269,569 5.1%   
CASH FLOW
From Operations Rs m7,25928,704 25.3%  
From Investments Rs m1,864-7,727 -24.1%  
From Financial Activity Rs m-9,273-21,326 43.5%  
Net Cashflow Rs m-150-314 47.8%  

Share Holding

Indian Promoters % 66.9 25.5 262.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.4 613.0%  
FIIs % 0.0 35.3 -  
ADR/GDR % 0.0 18.5 -  
Free float % 0.0 15.3 -  
Shareholders   68,381 75,885 90.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   CIPLA  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - PFIZER COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS